FDA Approvals, Commercialization, and Ongoing Clinical Trials - Research Report on Medtronic, Hologic, St. Jude, OPKO, and

   FDA Approvals, Commercialization, and Ongoing Clinical Trials - Research
           Report on Medtronic, Hologic, St. Jude, OPKO, and Wright

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 20, 2013

NEW YORK, August 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Medtronic,
Inc. (NYSE: MDT), Hologic, Inc. (NASDAQ: HOLX), St. Jude Medical, Inc. (NYSE:
STJ), OPKO Health, Inc. (NYSE: OPK), and Wright Medical Group, Inc. (NASDAQ:
WMGI). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Medtronic, Inc. Research Report

On August 15, 2013, Medtronic, Inc. (Medtronic) announced that it has
submitted its first pre-market approval (PMA) module to the US FDA for the
IN.PACT Admiral drug-eluting balloon for treatment of atherosclerotic lesions
in the superficial femoral artery (SFA). Tony Semedo, President of
Endovascular Therapies business at Medtronic said, "Pending FDA approval, we
remain on track to launch the IN.PACT Admiral drug-eluting balloon in the
United States during the second half calendar year 2015." According to the
Company, the PMA application for the IN.PACT Admiral drug-eluting balloon will
include clinical data from the IN.PACT SFA I and SFA II pivotal studies, the
IN.PACT SFA II pharmacokinetics (PK) study, and the IN.PACT Global study,
which have data of more than 1,000 enrolled patients. The Full Research Report
on Medtronic, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/bc94_MDT]

--

Hologic, Inc. Research Report

On August 8, 2013, Hologic, Inc. (Hologic) announced that it has commenced
commercialization of Horizon - a totally redesigned DXA imaging system for the
assessment of three critical health problems - osteoporosis, cardiovascular
disease, and obesity. The Company stated that the Horizon platform offers
extended technical capabilities, workflow efficiencies and better design
components in order to meet current and future clinician needs. Hologic also
informed that Horizon is being launched in the US and other countries. John
Jenkins, Vice President of Marketing for Specialty Imaging Products at Hologic
said, "We expect the technical advancements built into our Horizon platform
will set a new standard for image quality and operational efficiency." The
Full Research Report on Hologic, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/d132_HOLX]

--

St. Jude Medical, Inc. Research Report

On August 15, 2013, St. Jude Medical, Inc. (St. Jude) announced that it has
received US FDA approval and conducted first use of MediGuide Enabled Ablation
Catheters for treatment of specific irregular heartbeats. The Company claimed
that MediGuide technology is the first and only system that can reduce the
duration of radiation exposure during catheter ablation procedures thus
expanding the innovative MediGuide platform for St. Jude. St. Jude stated that
ablation catheters are used to create lesions during cardiac ablation
procedures while treating atrial flutter - a heart rhythm disorder. Dr. Chun
Hwang, Director Cardiac Electrophysiology from Utah Valley Regional Medical
Center said, "We are exposed to radiation multiple times a day, which adds up
quickly. Reducing the exposure time to radiation is a huge benefit for
everyone in the EP lab." The Full Research Report on St. Jude Medical, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b338_STJ]

--

OPKO Health, Inc. Research Report

On August 15, 2013, OPKO Health, Inc. (OPKO) announced that it has crossed 50%
enrollment in the second phase 3 trial of Rayaldy to treat patients with
secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease
(CKD), and vitamin D insufficiency. According to OPKO, the endpoints of both
the parallel conducted studies include vitamin D status and changes in serum
calcium, serum phosphorus and plasma intact parathyroid hormone (PTH). Phillip
Frost, M.D., Chairman and CEO OPKO said, "I am pleased to report that these
pivotal trials with Rayaldy Capsules are progressing as planned toward
completion in the first half of 2014. Top-line data are expected in mid-2014.
We believe Rayaldy will prove to be superior to high monthly doses of
prescription vitamin D[2], a common therapeutic approach which has been shown
unreliable in correcting vitamin D insufficiency in patients with chronic
kidney disease and generally ineffective in controlling elevated levels of
parathyroid hormone." The Full Research Report on OPKO Health, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/cd43_OPK]

--

Wright Medical Group, Inc. Research Report

On August 8, 2013, Wright Medical Group, Inc. (Wright) announced that it has
received a not approvable letter from the FDA in response to its PMA
application for Augment Bone Graft for use as an alternative to autograft in
hindfoot and ankle fusion procedures. According to Wright, in the letter FDA
stated that it is "concerned that the population enrolled was predominantly
low risk and, therefore, may not have warranted the use of either autograft or
Augment Bone Graft." Commenting further in its letter, FDA added it believes
that "it will be necessary to perform a new clinical study that evaluates the
use of Augment Bone Graft as a substitute for autograft in hindfoot and ankle
fusion procedures in a well-defined high-risk target population, where the use
of autograft would be clinically warranted." Robert Palmisano, President and
CEO of Wright, commented, "This is not what we expected, as we believed that
all of the FDA's concerns as outlined in their previous not approvable letter
from December 2011 had been fully and thoroughly addressed in the PMA
amendment that BioMimetic submitted in June 2012. We are continuing to study
the FDA's position and expect we will work collaboratively with the agency to
determine an appropriate path forward." The Full Research Report on Wright
Medical Group, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/1782_WMGI]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.